eValuator™ Inpatien `shboar Final act Accuracy Workflow Service Provider -12/31/18 国 | Your Service Provider Your Client . Overpayment ::::::: Streamline ,855.250 $ 370,982 . Health® ■ ■ ● ● ● ● ● ● ● ● ● ● ● ● ■ ■ ● ● ● ● ● ● ● ● ● ● . ■ ■ ■ ■ ■ ■ Second Quarter 2022 Earnings Presentation Apr > ■■●●●●●●● ■■■●●▲▲▲●●●■■■ Nasdaq: STRM ■■■●●●▲▲ ■ ■ ■ ● ● ▲ ......... ........ Disclosure Statement SAFE HARBOR STATEMENT: FORWARD-LOOKING DISCLOSURE This presentation contains "forward-looking statements" within the ...

Streamline Health Solutions, Inc. (NASDAQ:STRM) Q2 2022 Earnings Conference Call September 8, 2022 9:00 AM ET Company Participants Jacob Goldberger - Director of Investor Relations Wyche Green - President, Chairman and Chief Executive Officer Ben Stilwill - President and CEO, eValuator Solutions Jawad Shaikh - President and CEO, Avelead Solutions Tom Gibson - Senior Vice President and Chief Financial Officer Conference Call Participants Matt Hewitt - Craig-Hallum Capital Group Kyle Bauser - Lake Street Capi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to ____________ Commission File Number: 000-28132 STREAMLINE HEALTH SOLUTIONS, INC. (Exact name of registrant as specified in its charter) (State or o ...

Streamline Health Solutions, Inc. (NASDAQ:STRM) Q1 2022 Earnings Conference Call June 9, 2022 9:00 AM ET Company Participants Jacob Goldberger - Director of Investor Relations Wyche Green - President, Chairman and Chief Executive Officer Ben Stilwill - President and CEO, eValuator Solutions Jawad Shaikh - President and CEO, Avelead Solutions Tom Gibson - Senior Vice President and Chief Financial Officer Conference Call Participants Matt Hewitt - Craig-Hallum Capital Group Kyle Bauser - Lake Street Capital O ...

eValuator™ Inpatien `shboar Final act Accuracy Workflow Service Provider -12/31/18 国 | Your Service Provider our Client . -- $ 370,982 Health® ▲●●■■■ ■ ■ ● ● ● ● ● ● ● ● ● ● ● ● ■ ■ ● ● ● ● ● ● ● ● ● ● . ■ ■ First Quarter 2022 Earnings Presentation Apr > ■■■●●▲▲▲●●●■■■ Nasdaq: STRM HEREAL CA .......... Disclosure Statement SAFE HARBOR STATEMENT: FORWARD-LOOKING DISCLOSURE This presentation contains "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, ...

PART I. FINANCIAL INFORMATION This section presents the company's financial statements, management's analysis, market risk, and internal controls [Item 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS](index=4&type=section&id=Item%201.%20CONDENSED%20CONSOLIDATED%20FINANCIAL%20STATEMENTS) This section presents the unaudited condensed consolidated financial statements and detailed notes for the period ended April 30, 2022 [Condensed Consolidated Balance Sheets](index=4&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) This section provides a snapshot of the company's assets, liabilities, and equity at specific dates Condensed Consolidated Balance Sheets (April 30, 2022 vs. January 31, 2022, in thousands) | Metric | April 30, 2022 | January 31, 2022 | Change | % Change | | :-------------------- | :------------- | :--------------- | :----- | :------- | | Total Assets | $59,962 | $61,815 | $(1,853) | -3.00% | | Total Current Assets | $13,709 | $15,119 | $(1,410) | -9.33% | | Total Liabilities | $28,520 | $27,771 | $749 | 2.70% | | Total Stockholders' Equity | $31,442 | $34,044 | $(2,602) | -7.64% | [Unaudited Condensed Consolidated Statements of Operations](index=6&type=section&id=Unaudited%20Condensed%20Consolidated%20Statements%20of%20Operations) This section details the company's revenues, expenses, and net loss over specific periods Unaudited Condensed Consolidated Statements of Operations (Three Months Ended April 30, 2022 vs. 2021, in thousands) | Metric | April 30, 2022 | April 30, 2021 | Change | % Change | | :-------------------- | :------------- | :------------- | :----- | :------- | | Total Revenue | $5,935 | $2,951 | $2,984 | 101.12% | | Operating Loss | $(3,177) | $(2,455) | $(722) | 29.41% | | Net Loss | $(2,787) | $(2,142) | $(645) | 30.11% | | Basic Net Loss Per Share | $(0.06) | $(0.06) | $0.00 | 0.00% | | Diluted Net Loss Per Share | $(0.06) | $(0.06) | $0.00 | 0.00% | [Unaudited Condensed Consolidated Statements of Stockholders' Equity](index=7&type=section&id=Unaudited%20Condensed%20Consolidated%20Statements%20of%20Stockholders%27%20Equity) This section outlines changes in the company's equity components, including common stock and accumulated deficit Unaudited Condensed Consolidated Statements of Stockholders' Equity (April 30, 2022 vs. January 31, 2022, in thousands) | Metric | April 30, 2022 | January 31, 2022 | | :-------------------- | :------------- | :--------------- | | Common Stock | $481 | $478 | | Additional Paid in Capital | $119,407 | $119,225 | | Accumulated Deficit | $(88,446) | $(85,659) | | Total Stockholders' Equity | $31,442 | $34,044 | - Net loss for the three months ended April 30, 2022, was **$(2,787,000)**, contributing to the accumulated deficit[14](index=14&type=chunk) [Unaudited Condensed Consolidated Statements of Cash Flows](index=8&type=section&id=Unaudited%20Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) This section presents the cash inflows and outflows from operating, investing, and financing activities Unaudited Condensed Consolidated Statements of Cash Flows (Three Months Ended April 30, 2022 vs. 2021, in thousands) | Cash Flow Activity | April 30, 2022 | April 30, 2021 | | :-------------------------------- | :------------- | :------------- | | Net cash used in operating activities | $(1,270) | $(478) | | Net cash used by investing activities | $(519) | $(378) | | Net cash (used in) provided by financing activities | $(141) | $14,614 | | Net (decrease) increase in cash and cash equivalents | $(1,930) | $14,318 | | Cash and cash equivalents at end of period | $7,955 | $16,727 | [Notes to Unaudited Condensed Consolidated Financial Statements](index=9&type=section&id=Notes%20to%20Unaudited%20Condensed%20Consolidated%20Financial%20Statements) This section provides detailed explanations and disclosures supporting the condensed consolidated financial statements [NOTE 1 — BASIS OF PRESENTATION](index=9&type=section&id=NOTE%201%20%E2%80%94%20BASIS%20OF%20PRESENTATION) This note describes the company's operational segment and the accounting principles used in financial statement preparation - The Company operates as a single segment provider of healthcare information technology solutions and associated services, including licensing, SaaS, audit, and consulting services for hospitals in the US and Canada[21](index=21&type=chunk)[23](index=23&type=chunk) - Financial statements are prepared in accordance with GAAP, with certain information condensed or omitted per SEC Form 10-Q rules[22](index=22&type=chunk) [NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES](index=10&type=section&id=NOTE%202%20%E2%80%94%20SUMMARY%20OF%20SIGNIFICANT%20ACCOUNTING%20POLICIES) This note outlines key accounting policies, including revenue recognition, fair value, and share-based compensation - The fair value of the acquisition earnout liability decreased by **$500,000** from January 31, 2022, to April 30, 2022, recognized in 'other expense' in the statement of operations[31](index=31&type=chunk) Disaggregated Revenue by Type (Three Months Ended April 30, 2022 vs. 2021, in thousands) | Revenue Type | April 30, 2022 | April 30, 2021 | | :-------------------------- | :------------- | :------------- | | Recurring revenue | $3,941 | $2,234 | | Non-recurring revenue | $1,994 | $717 | | Total revenue | $5,935 | $2,951 | - The Company recognized **$2,288,000** in revenue from deferred revenues outstanding as of January 31, 2022, during the three months ended April 30, 2022[48](index=48&type=chunk) - Total compensation expense related to share-based awards was **$326,000** for the three months ended April 30, 2022, a decrease from **$565,000** in the prior comparable period[53](index=53&type=chunk) Non-routine Costs (Three Months Ended April 30, 2022 vs. 2021, in thousands) | Cost Type | April 30, 2022 | April 30, 2021 | | :----------------------- | :------------- | :------------- | | Professional fees | $90 | $91 | | Executive bonuses | — | $350 | | Total non-routine costs | $90 | $441 | [NOTE 3 — BUSINESS COMBINATION AND DIVESTITURE](index=17&type=section&id=NOTE%203%20%E2%80%94%20BUSINESS%20COMBINATION%20AND%20DIVESTITURE) This note details the Avelead acquisition, its financial impact, and the divestiture of the legacy ECM business - The Company acquired Avelead on August 16, 2021, for approximately **$29.7 million**, consisting of cash, common stock, and contingent consideration (earnout liability)[67](index=67&type=chunk)[70](index=70&type=chunk) - The acquisition earnout liability, re-measured at fair value, resulted in a **$500,000** valuation adjustment for the three months ended April 30, 2022[71](index=71&type=chunk) Avelead Acquisition: Allocation of Total Consideration to Net Assets (in thousands) | Asset Category | Amount | | :------------------------ | :----------- | | Net tangible assets (liabilities) | $(89) | | Goodwill | $12,377 | | Customer Relationships (SaaS) | $8,370 | | Customer Relationships (Consulting) | $1,330 | | Internally Developed Software | $6,380 | | Trademarks and Tradenames | $1,340 | | Net assets acquired and liabilities assumed | $29,708 | - For the three months ended April 30, 2022, Avelead contributed **$2,561,000** to consolidated revenues and **$(544,000)** to the consolidated continuing operations loss[74](index=74&type=chunk) - The Company divested its legacy Enterprise Content Management (ECM) business on February 24, 2020, reporting its results as discontinued operations[79](index=79&type=chunk) [NOTE 4 — OPERATING LEASES](index=21&type=section&id=NOTE%204%20%E2%80%94%20OPERATING%20LEASES) This note describes the company's operating lease arrangements, including right-of-use assets and liabilities - As of April 30, 2022, operating lease right-of-use assets totaled **$173,000**, with an associated current lease liability of **$188,000**[82](index=82&type=chunk) - The Company subleased its Alpharetta office space, expecting to receive **$292,000** over the 18-month term, and recorded **$48,000** as other income for the three months ended April 30, 2022[81](index=81&type=chunk)[142](index=142&type=chunk) - The Suwanee office lease, assumed with the Avelead acquisition, was renewed for twelve months in February 2022, incurring **$19,000** in rent expense for the three months ended April 30, 2022[85](index=85&type=chunk) [NOTE 5 — DEBT](index=22&type=section&id=NOTE%205%20%E2%80%94%20DEBT) This note details the company's term loan facility, interest rates, and compliance with debt covenants - On August 26, 2021, the Company entered into a Second Amended and Restated Loan and Security Agreement for a new **$10,000,000** term loan facility with Bridge Bank[86](index=86&type=chunk) - The term loan bears interest at the Prime Rate plus **1.5%**, with a Prime 'floor' rate of **3.25%**, and requires increasing monthly principal and interest payments after the first year[86](index=86&type=chunk)[87](index=87&type=chunk) Maximum Debt to ARR Ratio Covenants | Quarter Ending | Maximum Debt to ARR Ratio | | :------------- | :------------------------ | | October 31, 2021 | 0.80 to 1.00 | | January 31, 2022 | 0.75 to 1.00 | | April 30, 2022 | 0.65 to 1.00 | | July 31, 2022 | 0.55 to 1.00 | | October 31, 2022 | 0.50 to 1.00 | | January 31, 2023 | 0.45 to 1.00 | - The Company was in compliance with all covenants of the Second Amended and Restated Loan and Security Agreement for the period ended April 30, 2022[93](index=93&type=chunk) Outstanding Principal Balances on Term Loan (in thousands) | Metric | April 30, 2022 | January 31, 2022 | | :-------------- | :------------- | :--------------- | | Term loan | $10,000 | $10,000 | | Deferred financing cost | $(76) | $(96) | | Total | $9,924 | $9,904 | | Less: Current portion | $(375) | $(250) | | Non-current portion of debt | $9,549 | $9,654 | [NOTE 6 — INCOME TAXES](index=25&type=section&id=NOTE%206%20%E2%80%94%20INCOME%20TAXES) This note presents income tax expense, net operating loss carryforwards, and the effective income tax rate Income Tax Expense (Three Months Ended April 30, 2022 vs. 2021, in thousands) | Tax Type | April 30, 2022 | April 30, 2021 | | :---------------------- | :------------- | :------------- | | Federal | $(7) | - | | State | $(4) | $(9) | | Total current tax provision | $(11) | $(9) | - The Company had U.S. federal net operating loss carryforwards of **$46,250,000** and state NOLs of **$21,318,000** at January 31, 2022[98](index=98&type=chunk) - The effective income tax rate on continuing operations was approximately **21%**, differing from the statutory rate primarily due to a full valuation allowance on net deferred tax assets[99](index=99&type=chunk) [NOTE 7 — EQUITY](index=26&type=section&id=NOTE%207%20%E2%80%94%20EQUITY) This note discusses changes in equity, including public offerings, authorized shares, and stock incentive plans - On March 2, 2021, the Company completed a public offering of **10,062,500** shares of common stock at **$1.60** per share, generating gross proceeds of approximately **$16,100,000**[102](index=102&type=chunk) - The Company amended its Certificate of Incorporation on May 24, 2021, to increase authorized common stock from **45,000,000** to **65,000,000** shares[104](index=104&type=chunk) - The Streamline Health Solutions, Inc. Third Amended and Restated 2013 Stock Incentive Plan was amended to increase authorized shares for issuance by **2,000,000** to **8,223,246** shares[105](index=105&type=chunk) [NOTE 8 — COMMITMENTS AND CONTINGENCIES](index=27&type=section&id=NOTE%208%20%E2%80%94%20COMMITMENTS%20AND%20CONTINGENCIES) This note outlines commitments related to consulting agreements and other potential contingent liabilities - The Company has Master Services Agreements with 180 Consulting for various consulting services, under which 180 Consulting earned **577,147** shares cumulatively through April 30, 2022, and **56,070** shares for the three months ended April 30, 2022[108](index=108&type=chunk) - Fees paid to 180 Consulting totaled **$389,000** for the three months ended April 30, 2022, and an additional **$260,000** for services supporting Avelead products[108](index=108&type=chunk)[109](index=109&type=chunk) [NOTE 9 – DISCONTINUED OPERATIONS](index=28&type=section&id=NOTE%209%20%E2%80%93%20DISCONTINUED%20OPERATIONS) This note reports on the financial results and completion of transition services for discontinued operations Income from Discontinued Operations (Three Months Ended April 30, 2022 vs. 2021, in thousands) | Metric | April 30, 2022 | April 30, 2021 | | :-------------------- | :------------- | :------------- | | Revenues (Transition service fees) | — | $352 | | Expenses | — | $32 | | Income from discontinued operations | — | $320 | - The transition services related to the ECM Assets divestiture were completed in the third quarter of fiscal 2021[112](index=112&type=chunk) [NOTE 10 - RELATED PARTY TRANSACTIONS](index=29&type=section&id=NOTE%2010%20-%20RELATED%20PARTY%20TRANSACTIONS) This note discloses transactions with related parties, including research and development services and office leases - The Company incurred approximately **$16,000** in research and development services from AscendTek, LLC, a company owned by one of the Avelead Sellers, for the three months ended April 30, 2022[113](index=113&type=chunk) - An office lease for corporate space was assumed from an Avelead Seller, which was renewed for 12 months in February 2022[113](index=113&type=chunk) [NOTE 11 — SUBSEQUENT EVENTS](index=29&type=section&id=NOTE%2011%20%E2%80%94%20SUBSEQUENT%20EVENTS) This note confirms no material events requiring recognition or disclosure occurred after the reporting period - No events requiring recognition or disclosure in the condensed consolidated financial statements were identified after April 30, 2022[114](index=114&type=chunk) [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](index=30&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) This section provides management's perspective on financial condition, operations, non-GAAP measures, and liquidity [Forward-Looking Statements](index=30&type=section&id=Forward-Looking%20Statements) This section highlights forward-looking statements and key risk factors affecting future events and expectations - The report contains forward-looking statements regarding future events and expectations, which are subject to substantial risks and uncertainties[116](index=116&type=chunk) - Key risk factors include competitive products, product demand, market acceptance, the impact of COVID-19, and the successful integration of the Avelead acquisition[117](index=117&type=chunk) [Results of Operations](index=32&type=section&id=Results%20of%20Operations) This section analyzes the company's revenues, cost of sales, and various operating expenses over the period [Revenues](index=32&type=section&id=Revenues) This section details the breakdown of total revenue by type and explains the drivers of revenue changes Revenue Breakdown (Three Months Ended April 30, 2022 vs. 2021, in thousands) | Revenue Type | April 30, 2022 | April 30, 2021 | Change | % Change | | :-------------------------- | :------------- | :------------- | :----- | :------- | | Software licenses | $71 | $135 | $(64) | -47% | | Professional services | $1,244 | $78 | $1,166 | 1,495% | | Audit services | $679 | $504 | $175 | 35% | | Maintenance and support | $1,110 | $1,057 | $53 | 5% | | Software as a service | $2,831 | $1,177 | $1,654 | 141% | | Total Revenues | $5,935 | $2,951 | $2,984 | 101% | - The **101%** increase in total revenue was primarily driven by a **$1,654,000** increase in SaaS revenue (including **$1,534,000** from Avelead) and a **$1,166,000** increase in professional services revenue (including **$1,027,000** from Avelead)[123](index=123&type=chunk)[126](index=126&type=chunk)[128](index=128&type=chunk) - Software license revenue decreased by **47%** due to a shift from perpetual licenses to a SaaS model[125](index=125&type=chunk) [Cost of Sales](index=33&type=section&id=Cost%20of%20Sales) This section analyzes the components of cost of sales and the impact of the Avelead acquisition Cost of Sales Breakdown (Three Months Ended April 30, 2022 vs. 2021, in thousands) | Cost Type | April 30, 2022 | April 30, 2021 | Change | % Change | | :----------------------- | :------------- | :------------- | :----- | :------- | | Cost of software licenses | $101 | $137 | $(36) | -26% | | Cost of professional services | $1,126 | $214 | $912 | 426% | | Cost of audit services | $439 | $389 | $50 | 13% | | Cost of maintenance and support | $46 | $87 | $(41) | -47% | | Cost of software as a service | $1,497 | $610 | $887 | 145% | | Total cost of sales | $3,209 | $1,437 | $1,772 | 123% | - The overall cost of sales increased by **123%**, primarily due to the Avelead acquisition, which accounted for **$1,710,000** of the increase[129](index=129&type=chunk) - Cost of professional services increased by **$912,000**, with Avelead contributing **$903,000** to this increase[131](index=131&type=chunk) - Cost of SaaS solutions increased by **$887,000**, with Avelead contributing **$807,000**[134](index=134&type=chunk) [Selling, General and Administrative Expense](index=34&type=section&id=Selling,%20General%20and%20Administrative%20Expense) This section details changes in SG&A expenses, including the impact of the Avelead acquisition Selling, General and Administrative Expense (Three Months Ended April 30, 2022 vs. 2021, in thousands) | Expense Type | April 30, 2022 | April 30, 2021 | Change | % Change | | :-------------------------- | :------------- | :------------- | :----- | :------- | | General and administrative expenses | $2,779 | $1,732 | $1,047 | 60% | | Sales and marketing expenses | $1,722 | $819 | $903 | 110% | | Total selling, general, and administrative expense | $4,501 | $2,551 | $1,950 | 76% | - The **76%** increase in total SG&A was largely due to the Avelead acquisition, which contributed **$544,000** to general and administrative expenses and **$442,000** to sales and marketing expenses[135](index=135&type=chunk)[136](index=136&type=chunk) - Increased salaries and benefits for direct and indirect sales personnel also contributed to the rise in sales and marketing expenses[136](index=136&type=chunk) [Research and Development](index=35&type=section&id=Research%20and%20Development) This section analyzes R&D expenses and capitalized costs, including the impact of the Avelead acquisition Research and Development Costs (Three Months Ended April 30, 2022 vs. 2021, in thousands) | R&D Metric | April 30, 2022 | April 30, 2021 | Change | % Change | | :------------------------ | :------------- | :------------- | :----- | :------- | | Research and development expense | $1,312 | $977 | $335 | 34% | | Plus: Capitalized research and development cost | $510 | $378 | $132 | 35% | | Total research and development cost | $1,822 | $1,355 | $467 | 34% | - The **34%** increase in R&D expenses includes **$393,000** related to Avelead, partially offset by decreased spending with third-party vendors[137](index=137&type=chunk) - Capitalized R&D costs increased by **$132,000**, with **$208,000** attributed to Avelead[138](index=138&type=chunk) [Non-routine Costs](index=35&type=section&id=Non-routine%20Costs) This section details non-routine costs, primarily transaction costs related to the Avelead acquisition Non-routine Costs (Three Months Ended April 30, 2022 vs. 2021, in thousands) | Cost Type | April 30, 2022 | April 30, 2021 | Change | % Change | | :----------------------- | :------------- | :------------- | :----- | :------- | | Non-routine costs | $90 | $441 | $(351) | -80% | - Non-routine costs decreased by **80%** to **$90,000**, primarily consisting of transaction costs for the Avelead acquisition, compared to **$441,000** in the prior year which included executive bonuses[139](index=139&type=chunk) [Other Income (Expense)](index=36&type=section&id=Other%20Income%20(Expense)) This section explains changes in interest expense and other income, including acquisition-related adjustments Other Income (Expense) (Three Months Ended April 30, 2022 vs. 2021, in thousands) | Item | April 30, 2022 | April 30, 2021 | Change | % Change | | :------------------ | :------------- | :------------- | :----- | :------- | | Interest expense | $(132) | $(13) | $(119) | 915% | | Other | $533 | $15 | $518 | 3453% | | Total other income | $401 | $2 | $399 | 19,950% | - Interest expense increased significantly due to the **$10,000,000** term loan with Bridge Bank[141](index=141&type=chunk) - Other income includes a **$500,000** valuation adjustment related to Avelead acquisition earnout liabilities and **$48,000** from the Alpharetta office sublease[142](index=142&type=chunk) [Provision for Income Taxes](index=36&type=section&id=Provision%20for%20Income%20Taxes) This section details income tax expense and the company's substantial net operating loss carryforwards - Income tax expense was **$11,000** for the three months ended April 30, 2022, compared to **$9,000** in the prior year, primarily due to estimated federal, state, and local income tax provisions[143](index=143&type=chunk) - The Company maintains a substantial amount of net operating losses for tax purposes[143](index=143&type=chunk) [Use of Non-GAAP Financial Measures](index=36&type=section&id=Use%20of%20Non-GAAP%20Financial%20Measures) This section explains the use of non-GAAP measures like Adjusted EBITDA to supplement GAAP results - The Company uses non-GAAP financial measures (EBITDA, Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted EBITDA per diluted share) to provide greater insight into operating performance, supplementing GAAP results[144](index=144&type=chunk)[147](index=147&type=chunk) Adjusted EBITDA Reconciliation (Three Months Ended April 30, 2022 vs. 2021, in thousands, except per share data) | Metric | April 30, 2022 | April 30, 2021 | | :----------------------------------------- | :------------- | :------------- | | Loss from continuing operations | $(2,787) | $(2,462) | | EBITDA | $(1,561) | $(1,682) | | Adjusted EBITDA | $(1,693) | $(660) | | Adjusted EBITDA margin | (29)% | (22)% | | Adjusted EBITDA per adjusted diluted share | $(0.04) | $(0.02) | [Application of Critical Accounting Policies](index=39&type=section&id=Application%20of%20Critical%20Accounting%20Policies) This section confirms no material changes to critical accounting policies since the last annual report - There have been no material changes to the critical accounting policies disclosed in the Company's Annual Report on Form 10-K for the fiscal year ended January 31, 2022[156](index=156&type=chunk) [Liquidity and Capital Resources](index=39&type=section&id=Liquidity%20and%20Capital%20Resources) This section assesses the company's cash position, funding sufficiency, and compliance with debt covenants - Cash and cash equivalents were **$7,955,000** at April 30, 2022, down from **$9,885,000** at January 31, 2022[158](index=158&type=chunk)[164](index=164&type=chunk) - The Company believes its cash on hand and the **$10,000,000** term loan facility are sufficient to fund operations for the next twelve months[158](index=158&type=chunk)[164](index=164&type=chunk) - The Company was in compliance with all financial covenants under the Second Amended and Restated Loan and Security Agreement as of April 30, 2022[163](index=163&type=chunk) Operating Cash Flow Activities (Three Months Ended April 30, 2022 vs. 2021, in thousands) | Metric | April 30, 2022 | April 30, 2021 | | :------------------------------ | :------------- | :------------- | | Net loss from continuing operations | $(2,787) | $(2,462) | | Net cash used in operating activities | $(1,270) | $(478) | - Net cash used in investing activities was **$519,000** for the three months ended April 30, 2022, primarily for capitalized software development costs, an increase from **$378,000** in the prior year[167](index=167&type=chunk) - Net cash used in financing activities was **$141,000** for the three months ended April 30, 2022, compared to **$14,614,000** provided in the prior year due to the public offering of common stock[169](index=169&type=chunk) [Item 3. Quantitative and Qualitative Disclosures About Market Risk](index=41&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) This section notes the company's exemption from market risk disclosures as a smaller reporting company - The Company is exempt from providing quantitative and qualitative disclosures about market risk as it qualifies as a 'smaller reporting company'[170](index=170&type=chunk) [Item 4. Controls and Procedures](index=41&type=section&id=Item%204.%20Controls%20and%20Procedures) This section details the evaluation of disclosure controls and changes in internal control over financial reporting [Evaluation of Disclosure Controls and Procedures](index=41&type=section&id=Evaluation%20of%20Disclosure%20Controls%20and%20Procedures) This section confirms the effectiveness of disclosure controls, excluding the recently acquired Avelead - The CEO and CFO concluded that the Company's disclosure controls and procedures were effective as of April 30, 2022[171](index=171&type=chunk) - Avelead, acquired on August 16, 2021, was excluded from the scope of the assessment of disclosure controls and procedures[171](index=171&type=chunk) [Changes in Internal Control over Financial Reporting](index=42&type=section&id=Changes%20in%20Internal%20Control%20over%20Financial%20Reporting) This section notes the ongoing integration of Avelead's controls and no other material changes - Avelead was excluded from the scope of management's report on internal control over financial reporting for the year ended January 31, 2022, with integration of its controls ongoing[173](index=173&type=chunk) - No other material changes in internal control over financial reporting occurred during the quarter ended April 30, 2022, apart from the Avelead integration[173](index=173&type=chunk) PART II. OTHER INFORMATION This section covers additional information including risk factors, equity sales, exhibits, and signatures [Item 1A. Risk Factors](index=42&type=section&id=Item%201A.%20Risk%20Factors) This section refers to existing risk factors, noting no material changes but exacerbation by COVID-19 - No material changes to the risk factors disclosed in the Annual Report on Form 10-K for the year ended January 31, 2022, were identified[176](index=176&type=chunk) - Many existing risk factors have been, and are expected to continue to be, aggravated by the impact of the ongoing COVID-19 pandemic[176](index=176&type=chunk) [Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](index=43&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) This section details unregistered equity sales for services and acquisitions, and common stock repurchases - The Company issued **78,031** shares of common stock to 180 Consulting as compensation for services rendered during the three months ended January 31, 2022, in an unregistered private placement[178](index=178&type=chunk) - **5,021,972** shares of restricted common stock, valued at **$6.5 million**, were issued as part of the consideration for the Avelead acquisition in an unregistered private placement[179](index=179&type=chunk) Common Stock Repurchases (Three Months Ended April 30, 2022) | Period | Total Number of Shares Purchased | Average Price Paid per Share | | :--------------------- | :------------------------------- | :--------------------------- | | February 1 - February 28 | 35,676 | $1.44 | | March 1 - March 31 | 57,320 | $1.38 | | April 1 - April 30 | 2,705 | $1.60 | | Total | 95,701 | $1.41 | - The repurchased shares represent shares surrendered by employees to satisfy tax withholding obligations from vested restricted stock[180](index=180&type=chunk) [Item 6. Exhibits](index=44&type=section&id=Item%206.%20Exhibits) This section provides an index to the exhibits filed with the Form 10-Q, including corporate documents [Signatures](index=45&type=section&id=Signatures) This section contains the certifications of the Chief Executive Officer and Chief Financial Officer

Streamline Health Solutions, Inc. (NASDAQ:STRM) Q4 2021 Earnings Conference Call April 28, 2021 9:00 AM ET Company Participants Jacob Goldberger - Director of Investor Relations, FP&A Tee Green - President, Chairman & Chief Executive Officer Ben Stilwill - President and CEO, eValuator Solutions Jawad Shaikh - President and CEO, Avelead Solutions Tom Gibson - Chief Financial Officer Conference Call Participants Matt Hewitt - Craig-Hallum Capital Group Niraj Gupta - GCI Partners Operator Greetings, and welcom ...

eValuator™ Inpatien `shboar Final act Accuracy Workflow Service Provider -12/31/18 回 | Your Service Provider Your Client Overpayment :::::: Streamline ,855.250 $ 370,982 : Health® ........ ■ ■ ● ● ● ● ● ● ● ● ● ■ . . . ■■■■■ Fourth Quarter and Fiscal 2021 Earnings Presentation Apr > ■■●●●●●●●●■■ Nasdaq: STRM HEECOAAA HEROOAAO HEECOAA HEROOOAA Disclosure Statement SAFE HARBOR STATEMENT: FORWARD-LOOKING DISCLOSURE This presentation contains "forward-looking statements" within the meaning of the U.S. Private S ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________to___________ Commission File Number: 000-28132 STREAMLINE HEALTH SOLUTIONS, INC. (Exact name of registrant as specified in its charter) (Mark One) Delaware 31-1455414 ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (State or other jurisdiction of (I.R.S. E ...

Revenue Growth - Total revenues for the three months ended October 31, 2021, increased by 109% to $5,514,000 compared to $2,641,000 for the same period in 2020[137]. - Software as a Service (SaaS) revenue for the three months ended October 31, 2021, increased by 214% to $2,825,000 from $900,000 in the prior year[137]. - Professional services revenue for the three months ended October 31, 2021, increased by 486% to $944,000 compared to $161,000 in the same period last year[137]. - The company recorded $814,000 in professional services revenue from Avelead since its acquisition, contributing to the overall increase in professional services revenue[139]. Expenses - Selling, general, and administrative expenses for the three months ended October 31, 2021, increased by 51% to $3,439,000 from $2,283,000 in the prior year[147]. - Cost of sales for the three months ended October 31, 2021, increased by 77% to $2,623,000 compared to $1,479,000 in the same period last year[142]. - Research and development expenses for the three months ended October 31, 2021 were $1,339,000, a 78% increase from $753,000 in the prior year[149]. - Total research and development costs for the nine months ended October 31, 2021 were $4,328,000, a 24% increase from $3,491,000 in the prior year[150]. - Sales and marketing expenses increased by approximately $267,000 for the three and nine months ended October 31, 2021, primarily due to the Avelead acquisition and expansion of sales personnel[148]. - Non-routine costs for the three months ended October 31, 2021 were $1,933,000, representing a 100% increase compared to the prior year[151]. Financial Performance - For the three months ended October 31, 2021, the company reported a loss from continuing operations of $4,379,000 compared to a loss of $1,069,000 for the same period in 2020[166]. - The company reported a net loss from continuing operations of $(6,913,000) for the nine months ended October 31, 2021, compared to $(3,209,000) for the same period in 2020[178]. - Adjusted EBITDA for the nine months ended October 31, 2021 was $(1,737,000), an improvement from $(1,741,000) in the same period of 2020, with an adjusted EBITDA margin of (15%) compared to (21%) in 2020[166]. - The company had a diluted loss per share of $(0.10) for the three months ended October 31, 2021, compared to $(0.04) for the same period in 2020[166]. Cash Flow and Financing - The company had cash and cash equivalents of approximately $10,409,000 as of October 31, 2021, up from $2,409,000 at January 31, 2021[171]. - The company raised approximately $16.1 million from a public offering of 10,062,500 shares of common stock at $1.60 per share, which closed on March 2, 2021[171]. - The company invested $12,354,000 in Avelead during the nine months ended October 31, 2021, with net cash used in investing activities totaling $(12,620,000)[179]. - Net cash used in operating activities for the nine months ended October 31, 2021 was $(4,022,000), compared to $(3,683,000) for the same period in 2020[178]. - The company received a new term loan facility with a maximum principal amount of $10,000,000, which bears interest at a rate equal to the Prime Rate plus 1.5%[172]. - The company recorded a forgiveness of a PPP loan and accrued interest amounting to $2,327,000 for the nine months ended October 31, 2021[155]. Strategic Acquisitions - The acquisition of Avelead on August 16, 2021, is expected to enhance the company's revenue integrity solutions for healthcare providers[135]. - The company experienced a shift from perpetual software licenses to Software as a Service (SaaS) offerings, impacting revenue recognition[138]. - The company expects total research and development expenses to continue increasing due to ongoing projects related to Avelead and eValuator[150]. Other Financial Metrics - Total other income (expense) for the three months ended October 31, 2021 was $(555,000), a significant decrease from $2,000 in the prior year, reflecting a 27,850% change[154]. - Interest expense for the nine months ended October 31, 2021 was $(107,000), a 174% increase from $(39,000) in the prior year[154]. - The company has a substantial amount of net operating losses for federal and state income tax purposes, with an income tax expense of $9,000 for the nine months ended October 31, 2021[156]. - The company recorded a loss on exit from a membership agreement of $105,000 in the nine months ended October 31, 2020, which was not present in the current year[152]. - The company anticipates lower SaaS revenues in the fourth quarter due to slower contracting processes attributed to COVID-19[141]. - The company was in compliance with the covenants of the Second Amended Loan and Security Agreement for the period ended October 31, 2021[173].